Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK-guided Pembrolizumab in Advanced NSCLC
NCT05226728Phase 1Completed
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 18 months. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05226728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226728.